Monocentric Prospective Study into the Sustained Effect of Incobotulinumtoxin A (XEOMIN®) Botulinum Toxin in Chronic Refractory Migraine
| العنوان: | Monocentric Prospective Study into the Sustained Effect of Incobotulinumtoxin A (XEOMIN®) Botulinum Toxin in Chronic Refractory Migraine |
|---|---|
| المؤلفون: | Anne Le Floch, Stephane Bouly, Dimitri Renard, Marie De Verdal, Ioana Ion, Anne Wacongne, Alessandro Lozza, Giovanni Castelnovo |
| المصدر: | Toxins Volume 10 Issue 6 Toxins, Vol 10, Iss 6, p 221 (2018) |
| بيانات النشر: | Multidisciplinary Digital Publishing Institute, 2018. |
| سنة النشر: | 2018 |
| مصطلحات موضوعية: | Adult, Male, medicine.medical_specialty, Tension headache, Migraine Disorders, Health, Toxicology and Mutagenesis, lcsh:Medicine, chemical and pharmacologic phenomena, Toxicology, Article, Injections, Young Adult, 03 medical and health sciences, 0302 clinical medicine, Chronic Migraine, Quality of life, Refractory, immune system diseases, Internal medicine, hemic and lymphatic diseases, medicine, Humans, tension headache, 030212 general & internal medicine, Botulinum Toxins, Type A, Prospective cohort study, Aged, business.industry, refractory chronic migraine, medication overuse headache, lcsh:R, XEOMIN®, hemic and immune systems, prophylactic treatment, Middle Aged, medicine.disease, Botulinum toxin, Treatment Outcome, Neuromuscular Agents, Migraine, Female, business, 030217 neurology & neurosurgery, medicine.drug, Prophylactic treatment |
| الوصف: | Refractory chronic migraine is a disabling disorder impacting quality of life. BOTOX® (Onabotulinumtoxin A) is approved as a prophylactic treatment of chronic migraine in patients unresponsive to at least three prior preventive treatments. The objective of this study was to determine the prophylactic effect of 145 U XEOMIN® (Incobotulinumtoxin A) injected at 31 specific sites in adult patients with refractory chronic migraine. Sixty-one patients (8 men and 53 women, mean age 50) with migraine were recruited, including 20 patients with isolated chronic migraine, 18 patients with chronic migraine associating tension-type headache, 12 patients with migraine associating medication overuse headache, and 11 patients with episodic disabling migraine. The mean number of injections and duration of treatment per patient was 3.5 (range 2&ndash 13) and 21 (6&ndash 68) months, respectively. From baseline to first injection, 44 patients (73%) had > 50% reduction in frequency of migraine episodes, 29 patients (48%) showed > 50% reduction in number of headache days, and 28 patients (46%) had a > 50% reduction in drug intake. Stable response for all three parameters was observed after the last injection. XEOMIN® thus seems to represent an effective and sustained prophylactic treatment of chronic migraine. |
| وصف الملف: | application/pdf |
| اللغة: | English |
| تدمد: | 2072-6651 |
| DOI: | 10.3390/toxins10060221 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9fc98623c999c237de55654e7ab90cd5Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....9fc98623c999c237de55654e7ab90cd5 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 20726651 |
|---|---|
| DOI: | 10.3390/toxins10060221 |